NASDAQ:ANIX Anixa Biosciences (ANIX) Stock Forecast, Price & News $3.22 -0.06 (-1.83%) (As of 05/26/2023 08:46 PM ET) Add Compare Share Share Today's Range$3.17▼$3.4550-Day Range$3.22▼$5.9752-Week Range$2.77▼$6.45Volume43,500 shsAverage Volume78,661 shsMarket Capitalization$99.56 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Anixa Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside226.1% Upside$10.50 Price TargetShort InterestBearish2.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.43) to $2.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 starsMedical Sector727th out of 1,010 stocksPharmaceutical Preparations Industry368th out of 494 stocks 3.5 Analyst's Opinion Consensus RatingAnixa Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Anixa Biosciences has a forecasted upside of 226.1% from its current price of $3.22.Amount of Analyst CoverageAnixa Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.12% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Anixa Biosciences has recently increased by 4.24%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAnixa Biosciences does not currently pay a dividend.Dividend GrowthAnixa Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANIX. Previous Next 1.7 News and Social Media Coverage News SentimentAnixa Biosciences has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Anixa Biosciences this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for ANIX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows3 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anixa Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders20.40% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.21% of the stock of Anixa Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Anixa Biosciences are expected to grow in the coming year, from ($0.43) to $2.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anixa Biosciences is -7.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anixa Biosciences is -7.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnixa Biosciences has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Anixa Biosciences (NASDAQ:ANIX) StockAnixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics, and Patent Licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.Read More Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIX Stock News HeadlinesMay 23, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Anixa BiosciencesMay 23, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Anixa Biosciences (ANIX)May 29, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.May 22, 2023 | finance.yahoo.comAnixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical TrialApril 25, 2023 | finance.yahoo.comIs Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?April 19, 2023 | msn.comChardan Capital Reiterates Anixa Biosciences (ANIX) Buy RecommendationApril 19, 2023 | msn.comHC Wainwright & Co. Reiterates Anixa Biosciences (ANIX) Buy RecommendationApril 18, 2023 | markets.businessinsider.comExpert Ratings for Anixa BiosciencesMay 29, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!April 18, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Anixa Biosciences (ANIX), Gamida Cell (GMDA) and Satsuma Pharmaceuticals (STSA)April 17, 2023 | finance.yahoo.comAnixa Biosciences Clarifies Poster Presentation on Company WebsiteApril 17, 2023 | finance.yahoo.comAnixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer VaccineApril 14, 2023 | nypost.comOhio woman, the first person to receive a breast cancer vaccine in trial, awaits resultsApril 14, 2023 | msn.comOhio woman, the first person to receive a breast cancer vaccine in trial, awaits results: 'Very excited'April 14, 2023 | finance.yahoo.comHere's What Could Help ANIXA BIOSCIENCES INC (ANIX) Maintain Its Recent Price StrengthApril 13, 2023 | msn.comCleveland Clinic patient who received experimental breast cancer vaccine shares her storyApril 4, 2023 | americanbankingnews.comShort Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Decreases By 5.6%April 4, 2023 | americanbankingnews.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 5.6% in MarchMarch 29, 2023 | americanbankingnews.comAnixa Biosciences, Inc. Forecasted to Post FY2023 Earnings of ($0.45) Per Share (NASDAQ:ANIX)March 28, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Anixa Biosciences, Inc. Lifted by HC Wainwright (NASDAQ:ANIX)March 27, 2023 | finance.yahoo.comAnixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual MeetingMarch 26, 2023 | americanbankingnews.comAnixa Biosciences (NASDAQ:ANIX) Given New $12.00 Price Target at HC WainwrightMarch 25, 2023 | americanbankingnews.comAnixa Biosciences' (ANIX) "Buy" Rating Reiterated at Chardan CapitalMarch 24, 2023 | americanbankingnews.comResearch Analysts Issue Forecasts for Anixa Biosciences, Inc.'s Q1 2024 Earnings (NASDAQ:ANIX)March 24, 2023 | americanbankingnews.comAnixa Biosciences (NASDAQ:ANIX) Given New $9.00 Price Target at Chardan CapitalMarch 22, 2023 | markets.businessinsider.comChardan Capital Sticks to Its Buy Rating for Anixa Biosciences (ANIX)March 17, 2023 | markets.businessinsider.comChardan Capital Sticks to Its Buy Rating for Immunome (IMNM)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIX Company Calendar Last Earnings3/16/2023Today5/29/2023Next Earnings (Estimated)6/09/2023Fiscal Year End10/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANIX CUSIPN/A CIK715446 Webwww.anixa.com Phone(408) 708-9808Fax631-549-5974Employees4Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.50 High Stock Price Forecast$12.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+226.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-41.18% Return on Assets-38.97% Debt Debt-to-Equity RatioN/A Current Ratio22.81 Quick Ratio22.81 Sales & Book Value Annual Sales$510,000.00 Price / Sales195.22 Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book3.50Miscellaneous Outstanding Shares30,920,000Free Float24,616,000Market Cap$99.56 million OptionableNot Optionable Beta0.95 Key ExecutivesAmit D. KumarExecutive Chairman & Chief Executive OfficerMichael J. CatelaniPresident, COO, CFO & SecretaryPamela D. GarzoneChief Development OfficerKey CompetitorsGalectin TherapeuticsNASDAQ:GALTMediciNovaNASDAQ:MNOVParatek PharmaceuticalsNASDAQ:PRTKCelularityNASDAQ:CELUSCYNEXISNASDAQ:SCYXView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 65,961 shares on 5/16/2023Ownership: 0.504%Jane Street Group LLCBought 61,810 shares on 5/16/2023Ownership: 0.200%UBS Group AGBought 16,452 shares on 5/12/2023Ownership: 2.066%Stifel Financial CorpBought 20,000 shares on 5/12/2023Ownership: 0.162%Renaissance Technologies LLCSold 26,598 shares on 5/12/2023Ownership: 0.069%View All Institutional Transactions ANIX Stock - Frequently Asked Questions Should I buy or sell Anixa Biosciences stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIX shares. View ANIX analyst ratings or view top-rated stocks. What is Anixa Biosciences' stock price forecast for 2023? 2 equities research analysts have issued 12 month price objectives for Anixa Biosciences' stock. Their ANIX share price forecasts range from $9.00 to $12.00. On average, they predict the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 226.1% from the stock's current price. View analysts price targets for ANIX or view top-rated stocks among Wall Street analysts. How have ANIX shares performed in 2023? Anixa Biosciences' stock was trading at $4.25 at the start of the year. Since then, ANIX stock has decreased by 24.2% and is now trading at $3.22. View the best growth stocks for 2023 here. When is Anixa Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, June 9th 2023. View our ANIX earnings forecast. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences, Inc. (NASDAQ:ANIX) released its earnings results on Thursday, March, 16th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.08. What other stocks do shareholders of Anixa Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anixa Biosciences investors own include Cronos Group (CRON), Innovative Industrial Properties (IIPR), Roku (ROKU), Ally Financial (ALLY), Albireo Pharma (ALBO), Air Lease (AL), Akoustis Technologies (AKTS), Akero Therapeutics (AKRO), Aimmune Therapeutics (AIMT) and Advanced Emissions Solutions (ADES). What is Anixa Biosciences' stock symbol? Anixa Biosciences trades on the NASDAQ under the ticker symbol "ANIX." Who are Anixa Biosciences' major shareholders? Anixa Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include UBS Group AG (2.07%), BlackRock Inc. (0.80%), Susquehanna International Group LLP (0.50%), Jane Street Group LLC (0.20%), Stifel Financial Corp (0.16%) and Renaissance Technologies LLC (0.07%). Insiders that own company stock include Amit Kumar, Arnold M Baskies, Emily Gottschalk, Lewis H Titterton Jr and Michael Catelani. View institutional ownership trends. How do I buy shares of Anixa Biosciences? Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Anixa Biosciences' stock price today? One share of ANIX stock can currently be purchased for approximately $3.22. How much money does Anixa Biosciences make? Anixa Biosciences (NASDAQ:ANIX) has a market capitalization of $99.56 million and generates $510,000.00 in revenue each year. The company earns $-13,600,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. How can I contact Anixa Biosciences? Anixa Biosciences' mailing address is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. The official website for the company is www.anixa.com. The company can be reached via phone at (408) 708-9808, via email at mcatelani@ituscorp.com, or via fax at 631-549-5974. This page (NASDAQ:ANIX) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.